



Bal Pharma Limited

22.9.2017

To,
The Manager-Listing
BSE Limited
Mumbai.

To
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub: Proceedings of 30th Annual General Meeting ('AGM') held on 22.9.2017.
Ref : Scrip code 524824 for BSE and BALPH for NSE.

Pursuant to the provisions of Regulation 30 read with Schedule III Para A of Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that following business were transacted at the 30th Annual General Meeting of the Company held on 22.09.2017, at Bharatiya Vidya Bhavan, Race Course Road, Bangalore.


The Meeting commenced at 11.00 AM and ended at 12.45 PM.

Ordinary Business:

1. Adoption of audited financial statements of the Company for the financial year ended 31.3.2017, together with Board's report and Independent Auditors Report.
2. Declaration of dividend of Re.1/- per equity share of Rs.10/- each (i.e 10%), for the financial year ended 31.3.2017.
3. Reappointment of Dr.S.Prasanna as Director of the Company , who was retiring by rotation and offered himself for reappointment.
4. Appointment of NSVM & Associates, Chartered accountants as Statutory Auditors of the Company.

Special Business:

5. Approval of revision in the remuneration payable to Mr.Shaiesh Siroya, Managing Director.
6. Approval for renewing the Contract with Messrs Desa Marketing International.
7. Approval for change in the designation of Mr.Pramod Kumar.S, Director.
8. Ratification of the remuneration payable to the Cost Auditors of the Company.



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052, India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057/48

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813/19 Fax : 41570820

Kindly note that voting results will be announced after receipt of Scrutinizer's Report and the same will be submitted to the exchanges as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take this intimation on record.

Thanking you

For Bal Pharma Limited

Sanjay Agarwal
Sanjay Kumar Agarwal
Company Secretary

